What Hemafer-S treats: main uses and benefits

Hemafer-S is a medicinal product designed to address iron deficiency and maintain healthy iron levels in the body. It belongs to the category of iron supplements, specifically formulated to provide a bioavailable source of this essential mineral.

Main Uses

The primary application of Hemafer-S is the treatment and prevention of iron deficiency states. This includes:

• Iron Deficiency Anemia: A condition where the body lacks sufficient iron to produce adequate amounts of hemoglobin, the protein in red blood cells that carries oxygen to tissues.
• Latent Iron Deficiency: Situations where iron stores are depleted but hemoglobin levels have not yet fallen below the clinical threshold for anemia.
• Increased Iron Demand: Support during physiological periods where the body's need for iron rises, such as during rapid growth phases or pregnancy.

Benefits and Action

Iron is a fundamental component of various biological processes. By supplementing iron through Hemafer-S, several physiological benefits are supported:

• Hemoglobin Synthesis: The core benefit is providing the necessary building blocks for red blood cell production, which helps restore oxygen-carrying capacity throughout the body.
• Energy Metabolism: Iron acts as a cofactor for several enzymes involved in cellular energy production. Adequate levels help mitigate symptoms of fatigue and exhaustion associated with deficiency.
• Cognitive and Immune Support: Maintaining optimal iron levels is important for neurological function and the maintenance of a responsive immune system.

The formulation is intended to provide a stable source of iron that can be absorbed by the intestinal mucosa, gradually replenishing the body's internal iron stores (ferritin) to ensure long-term balance.

Who Can and Cannot Use Hemafer-S?

The eligibility for Hemafer-S (Iron Sucrose) is strictly defined by regulatory bodies and focuses on specific patient populations and contraindications.

---

Contraindicated Populations

Patients must not use this medicine if they have a known hypersensitivity to Iron Sucrose or any of its components. It is also contraindicated in patients with anaemia not caused by iron deficiency (e.g., hemolytic anaemia) or with evidence of iron overload (e.g., hemosiderosis).

---

Age and Condition-Based Eligibility

Population Group	Regulatory Status
Adults with IDA & CKD	Allowed (Primary Labeled Indication)
Children ge 2 years	Allowed (for iron maintenance in CKD)
Children <2 years	Use Not Established (Safety/Efficacy lacking)
Geriatric (ge 65 years)	Caution (Potential age-related decline in hepatic/renal function)

---

Use Restrictions

Use requires caution in populations with active infections, inflammatory conditions, or existing liver dysfunction where iron overload is a factor. For women, use is generally contraindicated during the first trimester of pregnancy, and caution is advised for nursing mothers as distribution into human milk is unknown.

Interaction Scope

Category	Official Regulatory Information
Medicinal product categories with documented interactions:	Oral iron preparations
Specific interacting medicines (if explicitly listed):	None listed other than the general class of oral iron preparations.
Mechanistic basis of interactions (only if stated in label):	Pharmacodynamic interaction leading to competitive inhibition of absorption.
Timing-based interaction rules (if applicable):	Oral iron must be initiated a minimum of five days after the last injection of Hemafer-S.
Population-specific interaction notes (if applicable):	None explicitly documented within the interaction sections of official regulatory labels.
Interaction-related restrictions:	Must not be co-administered with oral iron agents.

---

Interaction Classifications (High-Level)

Classification	Official Regulatory Information
Interaction severity classification (as defined in official documents):	Clinically significant interaction requiring mandatory timing separation.
Regulatory basis (EMA / FDA / etc.):	FDA Prescribing Information and international government health authority data sheets.
Interaction-context constraints (as defined in official documents):	Constraint applicable to the use of any oral iron preparation following intravenous administration.

---

Resulting interaction structure

Official interaction statements:

• The single formally documented interaction is a pharmacodynamic effect resulting in a reduction in the absorption of any concomitantly administered oral iron agent.
• There are no medicinal products explicitly listed as formal contraindications due to drug-drug interaction risk.
• Official regulatory labeling does not document specific interactions with CYP-mediated enzymes, drug transporters, food, alcohol, or herbal products.

Connection to the overall interaction profile (2–4 sentences):

The regulatory documentation defines the product’s interaction structure almost exclusively by the competitive relationship with oral iron preparations, which is a characteristic of parenteral iron products. This competitive interaction is officially described as reducing oral exposure, which formalizes the mandatory timing rule requiring a separation window before initiating oral iron. The profile otherwise reports the absence of documented metabolic or transporter interactions with other medicine classes.

Hemafer-S is a small molecule that enters systemic circulation and exerts its primary action by selectively engaging the beta-subunit of Prolyl Hydroxylase Domain (PHD) enzymes, specifically PHD1 and PHD2. This interaction establishes a non-competitive, allosteric inhibition, modifying the enzyme's active site structure. This molecular event represents the core mechanism of action.

The inhibition of PHD enzymes prevents the normal hydroxylation of specific Proline residues on the alpha-subunit of the Hypoxia-Inducible Factor (HIF) transcription complex. Under normal oxygen conditions, this hydroxylation tags HIF-alpha for binding to the Von Hippel-Lindau (VHL) E3 ubiquitin ligase complex, leading to its rapid degradation by the proteasome. By blocking the PHD-mediated hydroxylation, Hemafer-S stabilizes and accumulates HIF-alpha.

The accumulated HIF-alpha subunits translocate to the cell nucleus, where they dimerize with the HIF-beta subunit to form the active HIF transcription factor. This complex binds to Hypoxia-Response Elements (HREs) within the promoters of numerous target genes. The resulting transcriptional program modulates several key pathways, including the regulation of erythropoietin (EPO) synthesis in the kidney, which is a major system-level consequence of the drug's activity.

How Hemafer-S is Used

Hemafer-S (Iron Sucrose) is a prescription-only solution that must be administered only by the intravenous (IV) route in a clinical setting. The dosage is always expressed in milligrams (mg) of elemental iron.

Administration and Dosing Schedule

The total replacement course for an adult is typically 1000 mg of elemental iron. This course is divided into smaller doses based on the patient's Chronic Kidney Disease (CKD) status:

CKD Status	Adult Dose & Frequency (Total Course: 1000 mg)
Hemodialysis-Dependent (HDD-CKD)	100 mg per consecutive dialysis session (typically 10 sessions).
Non-Dialysis-Dependent (NDD-CKD)	200 mg per dose, administered on 5 different occasions over a 14-day period.
Peritoneal Dialysis-Dependent (PDD-CKD)	Given in 3 divided infusions (e.g., 300 mg, 300 mg, 400 mg) within a 28-day period.

Preparation and Procedural Rules

Administration involves strict adherence to preparation and rate requirements. The solution must be diluted only in 0.9% Sodium Chloride (NaCl) Injection to a concentration not lower than 1 mg/mL. The administration must be given via slow intravenous injection (over 2 to 5 minutes for a 100 mg dose) or infusion. For infusion, a 100 mg dose must be administered over a minimum of 15 minutes. In patients undergoing hemodialysis, the medicine should be administered early during the dialysis session.

Age-Specific Use

For pediatric patients (2 years of age and older), the labeled maintenance dose is 0.5 mg/kg of elemental iron, not to exceed 100 mg per dose, given over a 12-week period. Replacement dosing for children under 2 years of age is not established.

Research Evidence / Overview of Studies for Hemafer-S

Evidence for Iron Deficiency Anemia (IDA) When Oral Iron is Not Appropriate

Research exploring the use of Hemafer-S (Iron Sucrose) for Iron Deficiency Anemia (IDA) primarily involves short-term Randomized Controlled Trials (RCTs) that compare it against oral iron preparations or sometimes against a placebo. These studies focus on adult populations who have documented failure to respond to, or an inability to tolerate, oral forms of iron. The trials commonly use blood tests, or biomarkers, to record the body’s iron status at defined time points. Outcomes measured included changes in Hemoglobin (Hb) concentration, which tracks red blood cell health, and measurements of stored iron like Serum Ferritin and Transferrin Saturation (TSAT).

Research Context in Chronic Kidney Disease (CKD) Patients

This evidence stems from an extensive research structure, including large RCTs and analyses of real-world patient data from clinical registries, evaluating iron sucrose for treating IDA related to Chronic Kidney Disease (CKD). Research examined populations including adult and pediatric patients with CKD. Study outcomes examined included the change in iron indices and Hemoglobin levels, as well as monitoring the dose of Erythropoiesis-Stimulating Agents (ESAs) needed to manage anemia. Data show patterns related to maintaining iron indices over periods extending up to a year or more.

Long-Term Studies and Durability of Response

Most core studies for Hemafer-S primarily focused on achieving a rapid and short-term correction of iron deficiency, with typical follow-up periods ranging from one to six months. The data for certain groups remain insufficient when attempting to characterize the full durability of the change in iron status markers over several years. Long-term effects are not fully established, and more research is needed to understand the necessity and optimal frequency of re-treatment over many years.

Evidence in Special Populations

Iron sucrose was evaluated in research contexts involving pregnant women who had moderate-to-severe IDA, typically in the second and third trimesters. Studies focused on patient-reported outcomes, such as those related to physical activity and general fatigue levels. Research explored short-term changes in maternal Hemoglobin and Ferritin, and also examined outcomes relevant to the neonate, such as birth weight. Research has also been conducted on a limited basis in pediatric populations (e.g., children with CKD), but the results apply only to the populations studied, and data are still emerging.

Research Gaps and Areas of Uncertainty

Several areas of research continue to be explored. The certainty remains low for hard, long-term clinical endpoints (such as hospitalization rates or mortality) in the general IDA population. Furthermore, comparative evidence against newer intravenous iron formulations remains an area of active research. The available evidence, therefore, highlights what is known—and what is still uncertain—about the long-term profile of iron sucrose.

Common questions about Hemafer-S (FAQ)

Q: What is Hemafer-S used for?

A: Hemafer-S (Iron(III) Hydroxide Sucrose Complex) is an iron replacement product used to treat iron deficiency anemia in certain adult patients with chronic kidney disease (CKD).

This medication works to replenish the body's iron stores, which are necessary to produce healthy red blood cells that carry oxygen.

Q: How is Hemafer-S administered?

A: Hemafer-S is given as an intravenous (IV) infusion or a slow IV injection. It must be administered by a healthcare professional, typically a doctor or a nurse, in a clinical setting like a hospital or dialysis center.

It is not a medication that you take by mouth, such as a pill or a liquid.

Q: What are the possible side effects of Hemafer-S?

A: As with any medication, Hemafer-S can cause side effects. Common side effects may include:

• Changes in taste
• Headache or dizziness
• Low blood pressure (hypotension) or high blood pressure (hypertension)
• Nausea and/or vomiting
• Pain, swelling, or redness at the injection site
• Muscle cramps

Serious but rare side effects include severe allergic reactions (hypersensitivity reactions), which can sometimes be life-threatening. A healthcare provider will monitor you carefully during and after administration for any signs of a reaction.

Q: What should I tell my doctor before receiving Hemafer-S?

A: It's important to tell your doctor about your complete medical history, including:

• Any known allergies to iron products or any other ingredients in Hemafer-S.
• If you have a history of severe allergic reactions to any medications.
• If you have rheumatoid arthritis or asthma.
• If you have liver disease or kidney disease (beyond your current chronic kidney disease).
• A complete list of all other medications you are taking, including over-the-counter drugs, vitamins, and herbal supplements.

Q: Can Hemafer-S be used during pregnancy or while breastfeeding?

A: If you are pregnant, planning to become pregnant, or breastfeeding, you should discuss this with your doctor. Iron deficiency anemia is common during pregnancy, but your doctor will need to weigh the potential benefits against the risks. There is a risk of severe allergic reactions which may have serious consequences for the fetus.

If you are breastfeeding, your doctor will determine if this medication is appropriate for you. Human studies suggest that the drug does not pass into breastmilk in a significant amount and is generally considered safe if prescribed.

How to Store and Dispose of Hemafer-S (Iron Sucrose Solution)

The official labeling defines strict conditions for storing and handling Hemafer-S injection to maintain its stability.

Storage Requirements

The product must be stored at controlled room temperature, specifically maintained between 20 C and 25 C (68 F and 77 F). The vials must be protected from light and remain in the original carton until immediately prior to use. It is strictly required not to freeze or refrigerate the solution. The solution must be visually inspected before use and must not be used if it appears discolored or contains particulate matter.

Handling and Disposal

The vial is intended for single-dose use only, and any portion of the unused solution must be immediately discarded. All unused medicine and waste materials must be disposed of in accordance with local regulations, avoiding disposal in household trash or wastewater. It is mandatory to keep this product out of the sight and reach of children.